Reproductive Risk Factors of Inflammatory Breast Cancer according to Luminal, HER2-Overexpressing, and Triple-Negative Subtypes: A Case Comparison Study.


Journal

Oncology research and treatment
ISSN: 2296-5262
Titre abrégé: Oncol Res Treat
Pays: Switzerland
ID NLM: 101627692

Informations de publication

Date de publication:
2020
Historique:
received: 09 05 2019
accepted: 19 02 2020
pubmed: 24 3 2020
medline: 9 9 2020
entrez: 24 3 2020
Statut: ppublish

Résumé

We evaluated the risk factors of inflammatory breast cancer (IBC) compared to non-IBC and according to histological subtype. Cases of IBC (n = 160) and controls of non-IBC (n = 580) were collected from the cohort of breast cancer patients treated in two oncology centers matched based on age at cohort entry. Data about breast cancer risk factors were collected. We evaluated correlation and ORs using conditional logistic regression analysis for each case group versus the control group. We also evaluated those factors in three further subgroups: luminal (HR+, HER2-), HER2-overexpressing (HER2+, HR-), and triple-negative (TN) patients. Long duration of breastfeeding of ≥12 months (OR = 4.64, 95% CI 2.97-7.26), body mass index ≤25 (OR = 2.48, 95% CI 1.71-3.58), and use of oral contraceptives (OR = 2.48, 95% CI 1.62-3.84) were the most significant risk factors in favor of IBC compared to non-IBC. There was no impact of contraceptives use in the luminal subgroup and no impact of long duration of breastfeeding in the TN subgroup. The role of socioeconomic and educational levels was unclear. Age at menarche, age at first pregnancy, and age at menopause were nonsignificant risk factors of IBC. Reproductive risk factors were distinct in IBC patients reflecting the clinical entity of IBC.

Identifiants

pubmed: 32203954
pii: 000506691
doi: 10.1159/000506691
doi:

Substances chimiques

Contraceptives, Oral 0
Receptors, Estrogen 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

204-210

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Nesrine Mejri (N)

Medical Oncology Department, Abderrahmen Mami Hospital, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia, nesrinemejriturki2@gmail.com.
Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia, nesrinemejriturki2@gmail.com.

Houda El Benna (H)

Medical Oncology Department, Abderrahmen Mami Hospital, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia.
Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.

Haifa Rachdi (H)

Medical Oncology Department, Abderrahmen Mami Hospital, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia.

Soumaya Labidi (S)

Medical Oncology Department, Abderrahmen Mami Hospital, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia.
Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.

Mahdi Benna (M)

Medical Oncology Department, Abderrahmen Mami Hospital, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia.

Nouha Daoud (N)

Medical Oncology Department, Abderrahmen Mami Hospital, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia.

Yosr Hamdi (Y)

Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.

Sonia Abdelhak (S)

Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.

Hamouda Boussen (H)

Medical Oncology Department, Abderrahmen Mami Hospital, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia.
Laboratory of Biomedical Genomics and Oncogenetics, LR16IPT05, Institut Pasteur de Tunis, University of Tunis El Manar, Tunis, Tunisia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH